{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T23:34:23Z","timestamp":1778628863196,"version":"3.51.4"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,1,8]],"date-time":"2014-01-08T00:00:00Z","timestamp":1389139200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2014,2]]},"DOI":"10.1007\/s40263-013-0134-2","type":"journal-article","created":{"date-parts":[[2014,1,7]],"date-time":"2014-01-07T08:04:02Z","timestamp":1389081842000},"page":"171-183","source":"Crossref","is-referenced-by-count":10,"title":["Aripiprazole: A Review of Its Use in the Treatment of Manic Episodes in Adolescents with Bipolar I Disorder"],"prefix":"10.1007","volume":"28","author":[{"given":"Kate","family":"McKeage","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,1,8]]},"reference":[{"key":"134_CR1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders, 5th edn. Arlington: American Psychiatric Association. 2013. http:\/\/www.psych.org\/practice\/dsm\/dsm5 . Accessed 3 Oct 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"1","key":"134_CR2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/01.chi.0000242240.69678.c4","volume":"46","author":"J McClellan","year":"2007","unstructured":"McClellan J, Kowatch R, Findling R, the Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with bipolar disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(1):107\u201325.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"134_CR3","unstructured":"National Institute for Health and Clinical Excellence. Bipolar disorder: the management of bipolar disorder in adults, children and adolescents, in primary and secondary care. National Clinical Practice Guideline Number 38. 2006. http:\/\/www.nice.org.uk\/nicemedia\/live\/10990\/30194\/30194.pdf . Accessed 7 Oct 2013."},{"issue":"4","key":"134_CR4","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1177\/0269881109102919","volume":"23","author":"GM Goodwin","year":"2009","unstructured":"Goodwin GM, Consensus Group of the British Association for Psychopharmacology. Evidence-based guidelines for treating bipolar disorder: revised second edition\u2014recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2009;23(4):346\u201388.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"134_CR5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.31887\/DCNS.2009.11.1\/krmerikangas","volume":"11","author":"KR Merikangas","year":"2009","unstructured":"Merikangas KR, Nakamura EF, Kessler RC. Epidemiology of mental disorders in children and adolescents. Dialogues Clin Neurosci. 2009;11(1):7\u201320.","journal-title":"Dialogues Clin Neurosci"},{"key":"134_CR6","unstructured":"European Medicines Agency. Abilify 5\u00a0mg tablets: summary of product characteristics. 2009. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000471\/WC500020170.pdf . Accessed 20 Sept 2013."},{"issue":"1","key":"134_CR7","doi-asserted-by":"crossref","first-page":"133","DOI":"10.2165\/11208320-000000000-00000","volume":"72","author":"S Dhillon","year":"2012","unstructured":"Dhillon S. Aripiprazole: a review of its use in the management of mania in adults with bipolar I disorder. Drugs. 2012;72(1):133\u201362.","journal-title":"Drugs"},{"issue":"Suppl 1","key":"134_CR8","doi-asserted-by":"crossref","first-page":"S21","DOI":"10.1055\/s-2006-931485","volume":"39","author":"G Grunder","year":"2006","unstructured":"Grunder G, Kungel M, Ebrecht M, et al. Aripiprazole: pharmacodynamics of a dopamine partial agonist for the treatment of schizophrenia. Pharmacopsychiatry. 2006;39(Suppl 1):S21\u20135.","journal-title":"Pharmacopsychiatry"},{"issue":"15","key":"134_CR9","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2165\/00003495-200464150-00010","volume":"64","author":"T Swainston Harrison","year":"2004","unstructured":"Swainston Harrison T, Perry CM. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder. Drugs. 2004;64(15):1715\u201336.","journal-title":"Drugs"},{"issue":"3","key":"134_CR10","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ejphar.2011.07.020","volume":"668","author":"Y Tadori","year":"2011","unstructured":"Tadori Y, Forbes RA, McQuade RD, et al. In vitro pharmacology of aripiprazole, its metabolite and experimental dopamine partial agonists at human dopamine D2 and D3 receptors. Eur J Pharmacol. 2011;668(3):355\u201365.","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"134_CR11","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/S0893-133X(02)00304-4","volume":"27","author":"F Yokoi","year":"2002","unstructured":"Yokoi F, Grunder G, Biziere K, et al. Dopamin D2 and D3 receptor occupancy in normal human treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C] raclopride. Neuropsychopharmacology. 2002;27(2):248\u201359.","journal-title":"Neuropsychopharmacology"},{"issue":"9","key":"134_CR12","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1176\/appi.ajp.2007.06091479","volume":"164","author":"D Mamo","year":"2007","unstructured":"Mamo D, Graff A, Mizrahi R, et al. Differential effects of aripiprazole on D2, 5-HT2, and 5-HT1A receptor occupancy in patients with schizophrenia: a triple tracer PET study. Am J Psychiatry. 2007;164(9):1411\u20137.","journal-title":"Am J Psychiatry"},{"issue":"2","key":"134_CR13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1177\/0091270003261901","volume":"44","author":"S Mallikaarjun","year":"2004","unstructured":"Mallikaarjun S, Salazar DE, Bramer SL. Pharmacokinetics, tolerability, and safety of aripiprazole following multiple oral dosing in normal healthy volunteers. J Clin Pharmacol. 2004;44(2):179\u201387.","journal-title":"J Clin Pharmacol"},{"issue":"4","key":"134_CR14","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1097\/JCP.0b013e31817dd520","volume":"28","author":"RL Findling","year":"2008","unstructured":"Findling RL, Kauffman RE, Sallee FR, et al. Tolerability and pharmacokinetics of aripiprazole in children and adolescents with psychiatric disorders: an open-label, dose-escalation study. J Clin Psychopharmacol. 2008;28(4):441\u20136.","journal-title":"J Clin Psychopharmacol"},{"issue":"10","key":"134_CR15","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.4088\/JCP.09m05164yel","volume":"70","author":"RL Findling","year":"2009","unstructured":"Findling RL, Nyilas M, Forbes RA, et al. Acute treatment of pediatric bipolar I disorder, manic or mixed episode, with aripiprazole: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2009;70(10):1441\u201351.","journal-title":"J Clin Psychiatry"},{"issue":"2","key":"134_CR16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/bdi.12042","volume":"15","author":"RL Findling","year":"2013","unstructured":"Findling RL, Correll CU, Nyilas M, et al. Aripiprazole for the treatment of pediatric bipolar I disorder: a 30-week, randomized, placebo-controlled study. Bipolar Disord. 2013;15(2):138\u201349.","journal-title":"Bipolar Disord"},{"key":"134_CR17","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Assessment Report: Abilify (aripiprazole). 2012. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Assessment_Report_-_Variation\/human\/000471\/WC500138620.pdf . Accessed 17 Sep 2013."},{"issue":"4","key":"134_CR18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1089\/cap.2010.0100","volume":"21","author":"R Mankoski","year":"2011","unstructured":"Mankoski R, Zhao J, Carson WH, et al. Young mania rating scale line item analysis in pediatric subjects with bipolar I disorder treated with aripiprazole in a short-term, double-blind, randomized study. J Child Adolesc Psychopharmacol. 2011;21(4):359\u201364.","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"134_CR19","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jad.2009.02.010","volume":"118","author":"CA Soutullo","year":"2009","unstructured":"Soutullo CA, Escamilla-Canales I, Wozniak J, et al. Pediatric bipolar disorder in Spanish sample: features before and at time of diagnosis. J Affect Disord. 2009;118:39\u201347.","journal-title":"J Affect Disord"},{"issue":"4","key":"134_CR20","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1399-5618.2006.00342.x","volume":"8","author":"G Masi","year":"2006","unstructured":"Masi G, Perugi G, Toni C, et al. Attention-deficit hyperactivity disorder: bipolar comorbidity in children and adolescents. Bipolar Disord. 2006;8(4):373\u201381.","journal-title":"Bipolar Disord"},{"issue":"Suppl 3","key":"134_CR21","first-page":"5","volume":"66","author":"PE Keck","year":"2005","unstructured":"Keck PE. The role of second-generation antipsychotic monotherapy in the rapid control of acute bipolar mania. J Clin Psychiatry. 2005;66(Suppl 3):5\u201311.","journal-title":"J Clin Psychiatry"},{"issue":"1","key":"134_CR22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1097\/chi.0b013e31815b5cb1","volume":"47","author":"CU Correll","year":"2008","unstructured":"Correll CU. Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47(1):9\u201320.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"134_CR23","unstructured":"National Institute for Health and Clinical Excellence. Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder. NICE technology appraisal guidance 292. 2013. http:\/\/www.nice.org.uk\/nicemedia\/live\/14225\/64565\/64565.pdf . Accessed 9 Oct 2013."},{"key":"134_CR24","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1001\/archpsyc.62.12.1305","volume":"62","author":"G Kemmler","year":"2005","unstructured":"Kemmler G, Hummer M, Widschwendter C, et al. Dropout rates in placebo-controlled and active-control clinical trials of antipsychotic drugs: a meta-analysis. Arch Gen Psychiatry. 2005;62:1305\u201312.","journal-title":"Arch Gen Psychiatry"},{"issue":"6","key":"134_CR25","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1097\/chi.0b013e318040b25f","volume":"46","author":"CU Correll","year":"2007","unstructured":"Correll CU. Weight gain and metabolic effects of mood stabilizers and antipsychotics in pediatric bipolar disorder: a systematic review and pooled analysis of short-term trials. J Am Acad Child Adolesc Psychiatry. 2007;46(6):687\u2013700.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"134_CR26","doi-asserted-by":"crossref","unstructured":"Almandil NB, Liu Y, Murrya ML, et al. Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis. Pediatric Drugs. 2013;15:139\u201350.","DOI":"10.1007\/s40272-013-0016-6"},{"issue":"16","key":"134_CR27","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1001\/jama.2009.1549","volume":"302","author":"CU Correll","year":"2009","unstructured":"Correll CU, Manu P, Olshanskiy V, et al. Cardiometabolic risk of second-generation antipsychotics during first-time use in children and adolescents. JAMA. 2009;302(16):1765\u201373.","journal-title":"JAMA"},{"key":"134_CR28","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1192\/bjp.180.3.227","volume":"180","author":"R Das Gupta","year":"2002","unstructured":"Das Gupta R, Guest JF. Annual cost of bipolar disorder to UK society. Br J Psychiatry. 2002;180:227\u201333.","journal-title":"Br J Psychiatry"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-013-0134-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-013-0134-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-013-0134-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,21]],"date-time":"2022-03-21T18:57:24Z","timestamp":1647889044000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-013-0134-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1,8]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,2]]}},"alternative-id":["134"],"URL":"https:\/\/doi.org\/10.1007\/s40263-013-0134-2","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,1,8]]}}}